UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential
Credit Suisse initiated coverage on Genomic Health (NASDAQ: GHDX) with an Outperform rating and a $43 price target.
Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer."
Genomic Health closed at $36.15 on Monday.
Latest Ratings for GHDX
|Nov 2014||Credit Suisse||Maintains||Neutral|
|Nov 2014||Bank of America||Maintains||Underperform|
|Nov 2014||Canaccord Genuity||Maintains||Hold|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.